Preclinical studies using various cell culture and animal systems highlight the potential of recombinant rodent parvoviruses (recPVs) for cancer therapy. Production of these viruses is, however, not efficient and this hampers the clinical applications of these agents. In this study, we show that the adenovirus genes E2a, E4(orf6) and VA RNA increase the production of recPVs by more than 10-fold and reduce the time of production from 3 to 2 days in HEK293T cells. The helper effects of these genes can be observed with different recPVs, regardless of the nature and size of the inserted transgene. Furthermore, we generated a recombinant Adenovirus 5 carrying the parvovirus VP transcription unit. This helper, named Ad-VP, allows recPVs to be efficiently produced through a protocol based only on cell infection, making possible to use cell lines, such as NB324K, which are good producers of parvoviruses but are hardly transfectable. Hence, we could further improve viral titers and reduce time and costs of production. This Ad-VP helper-based protocol could be scaled up to a bioreactor format for the generation of the large amounts of recPVs needed for future clinical applications.
Introduction
Parvoviruses are icosahedral, single-stranded, DNA viruses. Their genome is about 5.1 kb and includes the P4 and P38 promoters, which drive the expression of non-structural (NS1 and NS2) and structural (VP1 and VP2) proteins, respectively. 1 The Parvovirus genus belongs to the Parvoviridae family. Another genus of the Parvoviridae family, the socalled Dependovirus includes the adeno-associated viruses (AAV), which are typically dependent on a helper virus, like adenovirus, for a productive infection cycle. 2 In contrast, parvoviruses are autonomous, that is, they are able to complete their productive cycle without a helper virus in appropriate host cells. This study focuses on rodent parvoviruses that we and others propose for use as oncolytic viruses in human anti-cancer therapy. 3 Rodent parvoviruses are non pathogenic for humans and show oncotropic and oncolytic properties that make them very attractive agents for cancer therapy. 3 To further enhance their intrinsic anti-neoplastic ability, recombinant viruses have been generated to deliver and express anti-tumor trangenes in cancer cells. The most commonly used strategy consists in replacing part of the VP capsid genes with a transgene of interest. 4 This puts the transgene under the transcriptional control of the genuine parvoviral P38 promoter, which is strongly transactivated by the parvoviral NS1 protein, leading to high but transient transgene expression in transformed cells. 5 Production of such recombinant parvoviruses (recPVs) requires the use of packaging cells providing the VP proteins in trans. Deletion of the capsid coding region in the parvoviral genome allows the insertion of transgenes up to approximately 2000 nt, although large VP deletions result in a significant reduction of recPVs production, probably because of the removal of important virus packaging cis-acting elements. 4 The recombinant parvoviral vectors generated in this way are replication-defective, speaking for their clinical safety. Examples of heterologous proteins successfully transduced by recPVs include a pro-drug-activating enzymes (the herpes simplex virus thymidine kinase 6 ), an oncotoxin (Apoptin 7 ) and various immunomodulatory factors (interleukin-2, monocyte chemotactic protein 1 and 3 and [8] [9] [10] [11] interferon-g-inducible protein 10 12, 13 ). Virions expressing these transgenes have improved anti-neoplastic activities in comparison with wild-type viruses.
One major challenge in the development of recPVs towards clinical applications is to significantly increase their yields. 5 Because of their non-replicative nature, their production depends largely on the transfection efficiency of the parvoviral genomic components into the packaging cell lines (in particular human embryonic kidney cells, HEK 293 or 293T). The use of packaging cell lines constitutively expressing the VP proteins did not significantly improved the production of recPVs. 14, 15 Parvoviruses were also genetically engineered and selected for a higher productivity. Along this line, hH-1 parvovirus was designed as a fusion of the right terminal part of MVMp with the rest of the H-1PV genome. 4 Its MVMp genomic part contains a reconstituted active origin of replication, harboring an additional NS1 nicking site, the MVM P4 promoter and 995 nucleotides of the MVM NS1/2-coding region. 4 The hH-1 virus has an improved virus DNA replication in comparison with the H-1, and hH-1 recombinants are produced with higher yields than H-1PV recombinants. Despite these improvements, recPVs production remains limited, calling for innovative strategies in order to increase recPV yields.
The helper activities of adenovirus towards AAV replication have been studied extensively. The adenoviral E1A protein is essential for AAV gene expression by binding and activating the AAV-2 P5 rep promoter. 16 Similarly, E2A, another adenoviral protein, activates the AAV-2 P5 promoter-driven transcription.
17 E2A also appears to cooperate with virus-associated RNA I (VA RNA) to enhance the translation of AAV-2 RNAs. 18 The adenoviral E4(orf6) enhances the conversion of single-stranded recombinant AAV-2 genomes into double-stranded forms, an important step of viral DNA replication both in vitro and in vivo. 19 VA RNA was also reported to support AAV-5 replication by physically interacting with the double-stranded RNA-activated protein kinase and impairing its ability to elicit an antiviral defense response through the inhibition of viral translation. 20 Studies with recombinant AAV-2 have confirmed that a small subset of adenoviral genes is sufficient for the helper effect. In HEK 293 cells, which provide the E1 gene in trans, the minimal set of genes for efficient recombinant AAV-2 production is E2a, E4(orf6) and the VA RNA gene. [21] [22] [23] A helper plasmid named pXX6, containing this set of genes, is currently used for the production of adenovirus-free recombinant AAV-2. 22 This plasmid allowed for AAV-2 production in a similar way as infectious adenovirus. 22, 24 There is some evidence supporting that adenovirus may also help replication of autonomous parvoviruses in cells that are normally not able to support the full parvoviral life-cycle. The adenovirus genes E2a, E4(orf6) and VA RNA were found to boost human erythrovirus B19 replication and production in HEK 293 cells, an otherwise non-permissive cell line for B19 production. 25 Furthermore, parvovirus H-1PV failed to initiate replication in secondary cultures of normal human embryonic lung cells, unless these cells are co-infected with adenovirus serotype 12. 26 In addition, adenovirus serotype 2 induced an increase in parvovirus MVMp DNA replication in HeLa cells, associated with re-localization of MVMp DNA from host nucleoli to adenovirus replication factories. 27 We hypothesized that, as in the case of AAV, recombinant vectors derived from rodent parvoviruses may benefit from the help of adenovirus gene products for their production. This study shows that adenovirus genes can indeed be used to increase and accelerate the production of recombinant parvoviruses. In addition, we generated a novel replication-defective recombinant Ad-5 vector harboring the parvovirus capsid gene unit (Ad-VP). The Ad-VP helper allows to circumvent the usage of transfection to express VP proteins in packaging cells, and allows multiplying recPVs production through co-infection only. This permits the utilization of highly permissive cells for parvovirus replication, such as NB324 K cells, which are difficult to transfect. Using this system, we succeeded in producing significantly higher titers of recPVs of the same quality as those obtained by conventional protocols. Importantly, the process can now be standardized, is reproducible and results in a reduction of both production times and costs.
Materials and methods
Cells HEK 293T and NB324 K (NBK) cells were cultivated in Dulbecco's modified Eagle medium or modified Eagle medium, respectively, supplemented with 10% or 5% modified Eagle medium fetal bovine serum, 2 mM L-Glutamine, 100 U per ml Penicillin and 100 mg ml
À1
Streptomycin. Cells were maintained at 37 1C in 5% CO 2 and 92% humidity.
Plasmids and viruses pH-1-EGFP was obtained by subcloning the EGFP gene from pChi-hH-1-EGFP 28 into the psr19-H-1-D800 4 using SacI/NotI restriction sites. phH-1-Luc was described as phH1D1600luc by Kestler et al. 4 The purified Ad-GFP virus was a kind gift from Dr Laurent Mailly (Institut de Virologie, Inserm U748, Strasbourg, France) 29 and was titrated on HEK 293T. Titers were expressed in green fluorescent units per ml (GFU per ml), with one GFU corresponding to one green cell at 48 h post-infection.
The pAd-VP helper plasmid was generated using the AdEasy Adenoviral Vector System (Agilent Technologies, Waldbronn, Germany; Stratagene Products) by recombining the pAd5DE1DE3 30 and pShuttle-CMV/VP(H-1) vectors into BJ5183 bacteria, according to the manufacturer's instructions. pShuttle-CMV/VP(H1) was generated by excising the VP region from pcDNA5-CMV/ VP(H-1) through PmeI digestion, and religating it into EcoRV-digested pShuttle-CMV vector (Agilent Technologies, Stratagene Products). pcDNA5-CMV/VP(H-1) was generated by subcloning the VP region from pVP-sub into pcDNA5/FRT/TO (Invitrogen, Darmstadt, Germany) using BamHI/XhoI restriction sites. pVP-sub was constructed by first inserting a HpaI restriction site into the polylinker of the pBluescript SK plasmid (pBSK, Stratagene), and then by subcloning the 2647-4680 nt fragment of the H-1PV genome (containing the VP transcription unit) from the p(BK)CMV/VP(H-1), 4 using HindIII/HpaI restriction sites.
Ad-VP helper virus was produced in HEK 293T through three rounds of infection, purified twice through a CsCl gradient centrifugation and titrated using the Adeno-X Rapid Titer Kit (Clontech, Saint-Germain-enLaye, France) providing adenovirus concentrations in Ad-X units per ml. Figures 1,3,4 and 5, were obtained by transfecting cells using Fugene HD (Roche, Mannheim, Germany) according to the manufacturer's instructions with minor modifications. Plasmids were diluted in serum-free medium to a final concentration of 20 ng ml
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and Fugene HD was then added at a 1:2.5 (mg DNA:ml Fugene) ratio. The mixture was incubated at room temperature for 30-60 min and subsequently added dropwise to cells. In the case of Figure 2 , transfection was achieved using polyethylenimine (Sigma, Steinheim, Germany), as described in. 31 For experiments performed with 6 cm plates, 8 Â 10 5 HEK 293T cells per dish were seeded, incubated for 24 h and transfected with an assortment from the following plasmids: recombinant parvovirus vector (1.2 mg), pCMV/ VP (2.4 mg), pXX6 (3 mg), pAd5DE1DE3 (5.2 mg) and pFRT/lacZeo (Invitrogen), used as a negative control up to a total of 5.2 mg. For experiments performed with 10 cm dishes or 175 cm 2 flasks, the HEK 293T cell number and plasmid quantities were proportionally adjusted and multiplied by factors of 2.5 and 6, respectively. In the case of Supplementary Figure 1 , 2.5 Â 10 5 HEK 293T cells were seeded per 6 cm plate and processed as described above for the same plate format.
Antibodies
The following antibodies were used for western blot analysis: rabbit polyclonal anti-NS1 SP8, 32 rabbit polyclonal anti-GFP (Santa Cruz, Santa Cruz, CA) and mouse monoclonal anti-actin (Clone C4, MP Biomedicals, Illkirch, France).
Luciferase assay
The luciferase Assay System (Promega) was used. A total of 2.5 Â 10 4 NBK cells per well were seeded in 48-well plates and infected on the next day with 0.1 ml of different dilutions of crude viral extracts. At 48 h post-infection, cells were washed with phosphate-buffered saline and lysed with 100 ml of 1 Â passive lysis buffer. A volume of 10 ml of the cell lysates were mixed with 50 ml of luciferase substrate and the resulting luminescence was measured for 10 s using Fluoroskan luminometer (Ascent FL, Thermo Labsystems, Dreieich, Germany). Quantitative real-time PCR. Crude cell extracts were digested with Benzonase Nuclease (Ultrapure grade (Sigma), 50 U per ml, 37 1C for 30 min) to remove genomic DNA and remaining transfected plasmids. To release viral DNA from virions, 10 ml of cell extract were mixed with 30 ml of alkaline lysis buffer (1 M NaOH in TE buffer) at 56 1C for 30 min. Lysis was stopped by adding 960 ml of 40 mM HCl.
Virus titration
Quantification of viral DNA was carried out by quantitative real-time PCR with the NS1-specific TaqMan probe, 5 0 -6-FAM-ATG CAG CCA GAC AGT Adenovirus genes enhance parvovirus production N El-Andaloussi et al TA-MGB-3 0 (Applied Biosystems, Darmstadt, Germany), using the following primers NS1-FOR: 5 0 -GCG CGG CAG AAT TCA AAC T-3 0 , NS1-REV: 5 0 -CCA CCT GGT TGA GCC ATC AT-3 0 . All quantitative real-time PCRs were carried out using an ABI Prism 7700 thermal cycler (Applied Biosystems), and analyzed by means of sodium dodecyl sulphate (SDS) 2.1 software (Applied Biosystems). A plasmid containing the NS1 sequence was serial diluted in the range of 10 1 -10 8 copies per reaction and was used to standardize the quantitative real-time PCR. Individual reaction mixtures (20 ml) consisted of 1 Â TaqMan Universal PCR Master Mix (Applied Biosystems), 0.3 mM labeled NS1-TaqMan probe, 0.3 mM of each primer and 3 ml of template.
Viral-DNA hybridization assay. NBK indicator cells were seeded in 6 cm dishes at a density of 5 Â 10 5 cells per dish. After 24 h, crude virus suspensions, serially diluted (in 1:10 steps), were used to infect the indicator cells in a total volume of 400 ml. After 1 h incubation at 37 1C and plates shaking every 10 min, 5 ml of medium was added to every dish. At 72 h post-infection, cell layers were washed with phosphate-buffered saline, and nitrocellulose filters of 25 mm diameter (Schleicher & Schuell, Dassel, Germany) were applied on top of the cells and moisturized with 100 ml of phosphate-buffered saline. The filters were subsequently put upside down on Whatman paper saturated with denaturation buffer (0.5 M NaOH and 1.5 M NaCl) for 5 min. Filters were then transferred to Whatman paper saturated with neutralizing buffer (0.5 M Tris/HCl (pH 7.2), 1.5 M NaCl and 1 mM EDTA) for additional 5 min. DNA was fixed by baking the filters at 80 1C for 2 h. Prehybridization was performed in 3 Â SSC (1 Â SSC is 0.15 M NaCl plus 0.015 M sodium citrate), 1% SDS, 5 mM EDTA, 10 Â Denhardt's solution and 100 mg ml À1 salmon sperm DNA, at 65 1C for 1 h. Hybridization was carried out by addition of the radioactive probe corresponding to the EcoRV (nt 385)-EcoRI (nt 1084) fragment of pMVM plasmid, purified by agarose gel electrophoresis, and labeled with [ 32 P]dCTP using the Megaprime DNA Labeling System (GE Healthcare, Munich, Germany). After incubation at 65 1C over night, filters were washed first in 3 Â SSC (pH 7), 1% SDS at 65 1C for 30 min, then in 0.3 Â SSC (pH 7) at 65 1C for 30 min. Subsequently, filters were placed on Whatman paper, wrapped in plastic foil and exposed to a radiographic film at À80 1C overnight. Cells supporting viral DNA amplification appear as black dots on the film because of the hybridization with radioactively labeled viral DNA. Virus titers were calculated as number of black dots Â dilution factor Â 7.5, and expressed in replication units per ml.
Plaque assay. NBK cells grown in 35% confluent monolayer were infected with serial dilutions of crude virus suspension for 1 h, followed by replacement of the inoculum with an overlay of 0.68% Bacto Agar (Becton, Dickinson and Company, Heidelberg, Germany) in Mimimum Essential Medium ( þ ) L-Glutamine (Gibco, Invitrogen, Darmstadt, Germany) containing 5% fetal bovine serum, 2 mM L-Glutamine, 100 U per ml Penicillin, 100 mg ml À1 Streptomycin. At 5 days post-infection, living cells were stained for 18 h by addition of neutral-red (0.2 mg ml À1 )-containing Bacto Agar (0.85%) diluted in phosphate-buffered saline. Plaques were counted and titers were expressed as plaque-forming units per ml.
DNA extraction and Southern blotting
For the analysis of the viral DNA intermediates produced during recombinant virus production, cell extracts were prepared in a mixture (1:1) of vTE buffer (10 mM TrisHCl (pH 8.7), 1 mM EDTA) and 2 Â Hirt buffer (20 mM Tris (pH 7.4), 20 mM EDTA and 1.2% SDS). After digestion of the extracts with proteinase K (400 mg ml À1 ) for 18 h at 46 1C under a rotation of 60 rounds per min, DNA was sheared by several passages through 0.5-and 0.4-mm needles, subjected to phenol-chloroform extraction, and finally to DpnI digestion to remove bacterial plasmids harboring viral genomes.
DNA samples (2 mg) were fractionated through 1% agarose gel electrophoresis. After in-gel DNA denaturation and neutralization, DNA was transferred onto Hybond-N nylon membrane (GE Healthcare) through a conventional Southern transfer procedure, and ultraviolet cross-linked to the membrane. The viral intermediates present on the membrane were then revealed by hybridization as described above for the viral DNA hybridization assay.
Results
Adenovirus gene products stimulate recombinant parvovirus production We investigated whether adenoviral genes are able to increase recPV production. Among the parvovirus backbones, we chose to use the chimeric molecular clone hH-1, because it shows a better DNA replication and productivity than its original MVM and H-1PV counterparts. 4 To this end, HEK 293T cells were transiently cotransfected with a recombinant hH-1 parvovirus plasmid carrying the GFP transgene (phH-1-GFP), a plasmid encoding the H-1 parvovirus capsid proteins (pCMV/VP) and the adenovirus 5-derived plasmid pXX6. pXX6 contains and expresses the E2a, E4(orf6) and VA RNA adenoviral genes and is sufficient to promote AAV production. 21, 22 Three days post-transfection, cells were lysed and hH-1-GFP virus production was assessed using a transduction assay in NBK indicator cells. Quantification of green cells by fluorescence microscopy showed that lysates derived from HEK 293T cells co-transfected with pXX6 contained more than 10-fold higher transducing particles than lysates from cells transfected with the parvoviral plasmids alone (Figure 1a) . Western blot analysis confirmed higher levels of GFP protein, together with higher levels of parvovirus NS1 product, in NBK cells infected with extracts derived from pXX6-cotransfected cells (Figure 1b) .
To investigate whether the production of recPV can be further improved by the presence of additional adenoviral elements, we compared pXX6 with a more complete adenoviral vector, pAd5DE1DE3 for their respective abilities to boost parvovirus production. Three days post-transfection, viral transduction assays were performed as described above. As shown in Figure 1c , both pAd5DE1DE3 and pXX6 significantly increased recPV production by more than 10-fold in comparison with controls. Parvovirus production in the presence of adenovirus helpers reached 10 6 GFP TU per ml, corresponding to an average of 5 TU per transfected producer cell. Both pAd5DE1DE3 and pXX6 led to a comparable increase in recPV production, indicating that the genetic material contained in pXX6 is sufficient to induce this effect.
To determine optimal conditions for the production of recPV, the experiment described above was repeated and compared with experiments in which the pXX6 plasmid transfection was carried out either concomitantly or 24 h before or after the transfection of parvovirus plasmids. Results showed that pXX6 enhanced recPV production in all conditions, with the highest increase observed when pXX6 was simultaneously co-transfected with the parvoviral plasmids (Supplementary Figure 1) .
To carefully quantify the amounts of recPV produced with the help of pXX6, HEK 293T cells were seeded into 175 cm 2 flasks, incubated for 24 h and co-transfected with phH-1-GFP and pCMV/VP, with or without pXX6. Seventy-two hours post-transfection, viruses were harvested as described above. The amounts of recPV, present in the cell lysates, were directly quantified using a parvovirus-specific quantitative-PCR and expressed as encapsidated viral genome per ml. In addition, the cell lysates were inoculated to NBK indicator cells, and virus titers were quantified by (i) the transductional assay described above and (ii) in situ hybridization assay, in which cells sustaining viral DNA replication were detected using a NS-specific radiolabeled probe. The concentrations of produced viruses measured by these biological assays were expressed as TU and Replication Units per ml, respectively. Figure 2 shows that these different assays all confirmed the significant increase of recPV production in the presence of pXX6 plasmid.
Next, we investigated whether pXX6 may have an impact on the generation of replication-competent parvoviruses (RCV), which takes place at a low frequency during recPV production as a result of homologous recombination between the recombinant parvoviral and the capsid gene containing vectors.
14 As these RCVs are unwanted contaminants of the recPV stocks, it is important to limit their occurrence during recPV production. RCVs were measured using a classical parvovirus plaque assay on NBK cells and their titers expressed in plaque-forming units per ml. The plaque-forming units/ TU ratio was not affected by pXX6 (Figure 2, right  panel) , showing that pXX6 does not increase the generation of RCV, thereby preserving the quality of the recombinant virus stocks produced.
Production of parvovirus harboring large transgenes (longer than 800 nt) is known to be impaired compared with production of recombinant containing shorter inserts (up to 800 nt). 4 The results obtained prompted us to verify, whether adenovirus genes could also boost the production of phH-1-Luc, which carries the luciferase gene (1656 nt long) instead of the previously used GFP transgene (731 nt). In parallel, we also tested the ability of pVAE2AE4-5, a vector carrying the same adenoviral genes as pXX6 but in a different plasmid backbone, to increase parvovirus production. 23 Furthermore, we determined whether the adenoviral helper genes could be applied by infection by using Ad5DE1DE3-CMV/GFP (Ad-GFP). Cells were treated with phH-1-Luc plus pCMV/VP and either co-transfected with one of the adenovirus helper plasmids (pXX6 or pVAE2AE4-5), or infected with Ad-GFP virus at multiplicity of infections ranging from 0.1 to 5 GFU per cell. Three days Figure 2 Recombinant parvovirus production is enhanced by pXX6 adenovirus-derived plasmid. HEK 293T cells, seeded in 175 cm 2 flasks were transfected with phH-1-GFP, pCMV/VP with ( þ ) or without (À) pXX6, and incubated for 72 h. Three days post-transfection, cells were collected and resuspended in 0.5 ml vTE buffer (50 mM Tris-HCl (pH 8.3), 0.5 mM EDTA) and lysed by three freeze and thaw cycles. Crude cell extracts were prepared and processed for virus titration through the measurement of their viral genome content (a) or capacity for infecting NBK indicator cells (as revealed by GFP production (b), viral DNA amplification (c) or plaque formation (d)). Columns represent the average values of three replicates with relative standard deviation bars. Numbers on top of columns indicate fold increase in recPV production in presence versus absence of pXX6. The PFU/TU ratio gives the fraction of replication-competent viruses generated during recPV production. PFU, plaque-forming units (determined by plaque assay); RU, replication units (determined by in situ hybridization); TU, transduction units (determined by counting green positive cells); Vg, viral genome (determined by q-PCR).
Adenovirus genes enhance parvovirus production N El-Andaloussi et al post-transfection/infection, the recPV yields were measured using a luciferase transduction assay. The results illustrated in Figure 3 confirmed the boosting effect (approximately 24-fold) of pXX6 on recPV production, generalizing the helper capacity of this vector for parvoviruses carrying different and longer transgenes. pVAE2AE4-5 increased parvovirus production to a similar extent, demonstrating that the helper elements lie within the adenoviral sequences shared by pXX6 and pVAE2AE4-5, and not in the plasmid backbone. Infection with recombinant adenovirus also increased parvovirus production, showing that the helper effect observed is independent of the method (transfection vs infection) used for introducing the adenoviral genetic elements into the producer cells. The highest increase in hH-1-Luc production, (circa 30-fold) was obtained using Ad-GFP at a multiplicity of infection of 1 GFU per cell. Under these conditions, all producer cells where successfully transduced by the recombinant adenovirus at day 2 post-infection (data not shown). This high rate of transduction is likely to be responsible for the higher increase in recPV production upon adenoviral gene transfer through infection compared with transfection. When Ad-GFP was used at higher multiplicity of infections, cellular toxicity was detected (data not shown), which probably accounts for the observed drop in parvovirus titers. Altogether, these results demonstrate that the presence of specific adenoviral genomic elements increases the yields of recPV production.
pXX6 accelerates recombinant parvovirus production
We then investigated whether pXX6 affected the kinetics of virus production, by carrying out a time course experiment. Cells were first co-transfected with phH-1-GFP and pCMV/VP with or without pXX6, and viral production was assessed at 12, 24, 48 and 72 h posttransfection. In agreement with above results, the presence of pXX6 greatly enhanced recPV production ( Figure 4 ). This stimulation could be observed from 24 h on increasing up to a maximum of more than 30 times at 48 h, when the production yield reached a plateau at about 1.5 Â 10 6 TU per ml. Virus production in the absence of pXX6 was much less efficient and significantly delayed, giving a maximal titer of 1.3 Â 10 5 GFU per ml at 72 h (which is the time at which recPVs are routinely harvested) (Figure 4a) . Thus, recPV production could not only be made more efficient but also shortened of about 24 h by supplying adenoviral helper elements. Southern blot analyses confirmed this conclusion. As illustrated in Figure 4b , parvoviral DNA monomeric and dimeric replicative forms were detected earlier (from 24 h on) and in much larger amounts. Therefore, pXX6 not only increases but also accelerates parvovirus DNA replication. Adenovirus genes enhance parvovirus production N El-Andaloussi et al pXX6 also increases recombinant parvovirus production in a transfection/infection-based protocol RecPVs are routinely produced by co-transfecting the producer cells with two plasmids: one encoding the VP capsid proteins, the other containing the remaining parvovirus genome harboring the transgene of interest. As viral infection is a better gene-delivery method than transfection, we aimed to further amplify recPV virions by inoculating them to permissive cells that had been transfected with the VP-containing plasmid. In this protocol, transfection would be limited to the VP-plasmid, whereas the parvovirus recombinant genome would be delivered through virus infection. Former experiments in our laboratory have, however, failed to produce recPVs using this method. In light of the helper functions of pXX6, we investigated whether the introduction of pXX6 may also stimulate the production of recPVs in the transfection/infection protocol. Cells were transfected with pCMV/VP in combination or not with pXX6, and then infected with hH-1-GFP. As shown in Figure 5 , a significant amplification of the virus inoculum (circa 17-fold) took place after infection of packaging cells, only in the presence of pXX6 plasmid. These results show that pXX6 does not only support recPV production in a protocol solely based on transfection but also when infectious parvoviral particles are used to transfer recombinant viral DNA. This supports the possible use of pXX6 in second-round amplification of recPVs.
Production of recPVs using the recombinant Ad-VP helper virus
To avoid the need of plasmid transfection for providing VP proteins in trans, we tested whether it was possible to amplify recPVs using an adenovirus that harbors not only the Ad genes needed to help parvovirus production but also the parvoviral VP transcription unit. To this end, we first cloned the VP region into pAd5DE1DE3 plasmid, 30 generating the pAd-VP helper construct. Ad-VP helper virus was routinely produced in HEK 293T at titers similar to the ones reported for Ad5DE1DE3 virus used as a control (data not shown).
This new Ad-VP helper virus was analyzed for its capacity to support recPV amplification through a protocol based only on infection, bypassing the need of transfection. This opened the possibility of using producer cell lines that are difficult to transfect but are more permissive than HEK 293T to parvovirus production, for example, NBK cells.
NBK cells were seeded in 6-well plates and concomitantly infected on the next day with purified Ad-VP helper virus and one of the following recPVs: hH-1-GFP, H-1-GFP, MVM-GFP or Chi-hH-1-GFP (see Materials and methods for description). Three days after coinfection, cells were lysed, and the recombinant viruses produced were titrated using the transduction assay. As before, plaque assays were performed to control for generation of RCV. As shown in Figure 6a , the helper adenovirus Ad-VP allowed all parvovirus recombinants to get amplified in NBK cells. When compared with hH-1-GFP production through transfection and in presence of pXX6 (Figure 1c) , the infection protocol led to a significant improvement (about eight-fold) in the yields of recPVs produced. Importantly, this procedure did not increase the rate of RCV contamination in comparison with production carried out in the absence of Ad-VP helper (Figure 6b ). These results highlight the potential of the Ad-VP helper to enhance the efficiency of recPV production.
Discussion
High titer production of parvoviruses has remained a major challenge and a bottleneck for the clinic application of these viruses. 5 Here, we showed that the use of adenoviral genes enhances by more than 10-fold the production of recPVs in HEK 293T cells. Transfection of HEK 293T cells with either pAd5DE1DE3 (containing all adenovirus-5 genes with the exception of E1 and E3), pXX6 or pVAE2AE4-5 (both containing the adenovirus-5 genes E2a, E4(orf6) and VA RNA) led to a comparable increase in recPV production. These results indicate that, similarly to AAV and B19, 22, 23 the adenoviral genes contained in pXX6 are sufficient to increase recPV production. It is likely that the protocols used here can be further improved for instance by determining the most appropriate timing for the delivery of the adenovirus genes to producer cells or the optimal molar ratio of the three plasmids used for the production (parvovirus vector: Adenovirus genes enhance parvovirus production N El-Andaloussi et al capsid vector: adenoviral helper). In this study, we used a 1:2:1 ratio, chosen based on previously published results concerning AAV production. 4, 22, 24 The mechanism(s) underlying the effect of the adenovirus genes on recPV production and which elements, among the ones expressed by the pXX6 plasmid, are required for the amplification, remain uncharacterized. Similar studies conducted with adeno-associated viruses showed that E2a is the major contributor to the adenoviral helper effect on AAV-2, 23 whereas VA RNA sustains the AAV-5 replication by blocking double-stranded RNA-activated protein kinase activation and suppressing the antiviral cellular response. 20 This study shows that pXX6 significantly increases and accelerates viral DNA replication during the production of recPVs. In agreement with these results, adenovirus 2 facilitated DNA replication of the closely related parvovirus MVM, 27 whereas pXX6 adenoviral vector, enabled the erythrovirus B19 to replicate its DNA and produce infectious progeny particles in non-permissive HEK 293 cells. 25 This led us to speculate that one or several gene products of pXX6 may directly modulate parvoviral DNA replication or set up favorable cellular conditions for that. In support of an active role of adenovirus genes in parvoviral DNA replication, it has been shown that E4(orf6) participates in the conversion of the singlestranded AAV-2 viral genome into the double-stranded replicative forms. 19 The amount of capsid protein is also a limiting factor for the efficient production of recPVs. 14, 33 Elements encoded by pXX6 may stimulate the CMV promoter, which controls the expression of the VP transcriptional unit in the VP plasmid, resulting in an increase in the levels of the capsid proteins and consequentially in recPV production. In keeping with this possibility, the adenoviral E4 gene was reported to activate the CMV promoter. 34 Parvoviruses have a limited packaging capacity and can only accommodate 150-300 additional nucleotides, corresponding to 3-6% of their genome. To construct recPVs, it is therefore necessary to delete a part of their genome of approximately the same size as the inserted transgene. The deletion is usually introduced in the parvoviral VP transcription unit, for the sake of preserving the capacity of the vector for DNA replication. 5 The replacement of a large part of the VP region (more than 800 bp) affects recPV production, probably because it eliminates cis-acting elements that are required for a proper viral DNA packaging. 4 Indeed, recPVs harboring large transgenes are produced at a very low efficiency. Adenoviral helper genes, were found to induce a similar enhancement of the production of recPVs harboring either a small transgene such as GFP (700 bp) or a larger transgene, like the luciferase (1600 nt). Adenovirus genes can then be used for improving the yields of otherwise difficult to produce recPVs, enlarging the spectrum of therapeutic transgenes that can be inserted into the parvovirus genome.
Another important aspect to take in account during recPVs production is the quality of the final viral stocks produced. In particular, the occurrence of RCVs must be minimized. These RCVs are formed during recPV production as a result of spontaneous recombination between the recombinant parvovirus and VP-containing constructs. It is noteworthy that the adenovirus functions boosting recPV production did not enhance the recombination risk, thereby preserving the quality of recPV stocks regarding their contamination with RCVs. Currently, the protocol in use for the production of recPVs is based on the transfection of a producer cell line, generally HEK 293T, with two plasmids: one containing the recombinant parvovirus genome, in which the transgene of interest is inserted and another that harbors the VP capsid transcription unit. Therefore, recPVs yields heavily depend on the competence of producer cells for both transfection and parvovirus replication. These two requirements are not obvious to reconcile, as the NBK cells routinely chosen for their high permissiveness to parvovirus productive infection are difficult to transfect. Therefore, an important outcome of this study was to show that the adenoviral booster genes and parvoviral VP transcription unit can be delivered together through single infection with a recombinant adenovirus (Ad-VP). This allowed recPV stocks to be amplified by coinfection of highly permissive cells with previously produced recPVs and Ad-VP, irrespective of the competence of these cells for transfection. Using this strategy, we could produce recPVs in 50-300-fold larger amounts compared with conventional procedures. It is worth mentioning that previous attempts at amplifying recPVs in secondary rounds of infection of VP-expressing packaging cells, in the absence of adenoviral helper functions, met with little success. 14, 15 Ad-VP thus appears to be a unique tool to achieve this infection-mediated amplification. The use of Ad-VP offers several important advantages over conventional methods regarding the efficiency, duration, complexity and costs of recPV production, because of its ability to bypass transfection and boost parvovirus replication, and its failure to promote RCV generation. By overcoming the limitation of current methods to the use of transfection-competent producer cells, the Ad-VP protocol should allow a broader range of permissive cells to be screened for best candidates in terms of recPV yields and up scaling possibilities (for example, use of bioreactors with cells in suspension).
Although further optimization of the protocol may be required, this study produced proof of concept that recombinant adenovirus can be used to amplify recPV stocks, thereby paving the way to future clinical application of these interesting anti-neoplastic agents.
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